GSK plc (GSK,GSK.L) has entered into an agreement to acquire Boston Pharmaceuticals' BP Asset IX Inc. for $2 billion in total cash consideration, comprising a $1.2 billion upfront payment and up to $800 million in success-based milestone payments. Additionally, GSK will assume responsibility for milestone payments and tiered royalties owed to Novartis Pharma AG for efimosfermin.
Efimosfermin is a phase III-ready, investigational specialty medicine with the potential to be best-in-class for treating and preventing the progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with the possibility of an additional $800 million in milestone payments.
GSK will account for the transaction as a business combination. The deal is subject to customary conditions, including regulatory clearances under the Hart-Scott-Rodino Act in the US.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.